{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:41:04Z","timestamp":1782880864608,"version":"3.54.5"},"reference-count":50,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Ministry of Health and Warfare, Taiwan","award":["MOHW107-TDU-B-212-114011"],"award-info":[{"award-number":["MOHW107-TDU-B-212-114011"]}]},{"name":"the Ministry of Health and Warfare, Taiwan","award":["MOHW108-TDU-B-212-124011"],"award-info":[{"award-number":["MOHW108-TDU-B-212-124011"]}]},{"name":"the Ministry of Health and Warfare, Taiwan","award":["MOHW109-TDU-B-212-134011"],"award-info":[{"award-number":["MOHW109-TDU-B-212-134011"]}]},{"name":"the Ministry of Health and Warfare, Taiwan","award":["MOHW110-TDU-B-212-144011"],"award-info":[{"award-number":["MOHW110-TDU-B-212-144011"]}]},{"name":"the Ministry of Health and Warfare, Taiwan","award":["XPRPG3G0121~4"],"award-info":[{"award-number":["XPRPG3G0121~4"]}]},{"name":"the Ministry of Health and Warfare, Taiwan","award":["CMRPG3D1521~4"],"award-info":[{"award-number":["CMRPG3D1521~4"]}]},{"name":"Celgene","award":["MOHW107-TDU-B-212-114011"],"award-info":[{"award-number":["MOHW107-TDU-B-212-114011"]}]},{"name":"Celgene","award":["MOHW108-TDU-B-212-124011"],"award-info":[{"award-number":["MOHW108-TDU-B-212-124011"]}]},{"name":"Celgene","award":["MOHW109-TDU-B-212-134011"],"award-info":[{"award-number":["MOHW109-TDU-B-212-134011"]}]},{"name":"Celgene","award":["MOHW110-TDU-B-212-144011"],"award-info":[{"award-number":["MOHW110-TDU-B-212-144011"]}]},{"name":"Celgene","award":["XPRPG3G0121~4"],"award-info":[{"award-number":["XPRPG3G0121~4"]}]},{"name":"Celgene","award":["CMRPG3D1521~4"],"award-info":[{"award-number":["CMRPG3D1521~4"]}]},{"name":"Chang Gung Memorial Hospital","award":["MOHW107-TDU-B-212-114011"],"award-info":[{"award-number":["MOHW107-TDU-B-212-114011"]}]},{"name":"Chang Gung Memorial Hospital","award":["MOHW108-TDU-B-212-124011"],"award-info":[{"award-number":["MOHW108-TDU-B-212-124011"]}]},{"name":"Chang Gung Memorial Hospital","award":["MOHW109-TDU-B-212-134011"],"award-info":[{"award-number":["MOHW109-TDU-B-212-134011"]}]},{"name":"Chang Gung Memorial Hospital","award":["MOHW110-TDU-B-212-144011"],"award-info":[{"award-number":["MOHW110-TDU-B-212-144011"]}]},{"name":"Chang Gung Memorial Hospital","award":["XPRPG3G0121~4"],"award-info":[{"award-number":["XPRPG3G0121~4"]}]},{"name":"Chang Gung Memorial Hospital","award":["CMRPG3D1521~4"],"award-info":[{"award-number":["CMRPG3D1521~4"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Locked nucleic acid quantitative Real-Time PCR (LNA-qPCR) for IDH1\/2 mutations in AML measurable residual disease (MRD) detection is rarely reported. LNA-qPCR was applied to quantify IDH1\/2 mutants MRD kinetics in bone marrow from 88 IDH1\/2-mutated AML patients, and correlated with NPM1-MRD, clinical characteristics, and outcomes. The median normalized copy number (NCN) of IDH1\/2 mutants decreased significantly from 53,228 (range 87\u2013980,686)\/ALB \u00d7 106 at diagnosis to 773 (range 1.5\u2013103,600)\/ALB \u00d7 106 at first complete remission (CR). IDH1\/2 LNA-qPCR MRD was concordant with remission status or NPM1-MRD in 79.5% (70\/88) of patients. Younger patients and patients with FLT3 mutations had higher concordance. The Spearman correlation coefficient (rs) and concordance rate between the log reduction of IDH1\/2 LNA-qPCR and NPM1-MRD were 0.68 and 81% (K = 0.63, 95% CI 0.50\u20130.74), respectively. IDH1\/2-MRD &gt; 2 log reduction at first CR predicted significantly better relapse-free survival (3-year RFS rates 52.9% vs. 31.9%, p = 0.007) and cumulative incidence of relapse (3-year CIR rates 44.5% vs. 64.5%, p = 0.012) compared to IDH1\/2-MRD \u2264 2 log reduction. IDH1\/2-MRD &gt; 2 log reduction during consolidation is also associated with a significantly lower CIR rate than IDH1\/2-MRD \u2264 2 log reduction (3-year CIR rates 42.3% vs. 68.8%, p = 0.019). LNA-qPCR for IDH1\/2 mutation is a potential MRD technique to predict relapse in IDH1\/2-mutated AML patients, especially for those with IDH1\/2 MRD &gt; 2 log reduction at first CR or a concurrent FLT3 mutation.<\/jats:p>","DOI":"10.3390\/cancers14246205","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T02:54:02Z","timestamp":1671159242000},"page":"6205","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Measurable Residual Disease Monitoring by Locked Nucleic Acid Quantitative Real-Time PCR Assay for IDH1\/2 Mutation in Adult AML"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3586-5317","authenticated-orcid":false,"given":"Hsiao-Wen","family":"Kao","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 333423, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chung","family":"Kuo","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 333423, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 333323, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jung","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 333423, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 333423, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 333323, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Fen","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 333423, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chein-Fuang","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 333423, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shin","family":"Hung","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 333423, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Liang","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 333423, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Wei","family":"Ou","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 333423, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yu","family":"Lien","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung 404327, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hou","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 333423, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Chiayi, Chiayi 613016, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1866-7922","authenticated-orcid":false,"given":"Lee-Yung","family":"Shih","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 333423, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 333323, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2013.12.016","article-title":"Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance","volume":"14","author":"Kats","year":"2014","journal-title":"Cell Stem Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1231677","article-title":"(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible","volume":"339","author":"Losman","year":"2013","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20092506","article-title":"Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations","volume":"207","author":"Gross","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2009-11-250878","article-title":"Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: Prevalence and prognostic value","volume":"116","author":"Abbas","year":"2010","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1200\/JCO.2010.28.2285","article-title":"Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group","volume":"28","author":"Boissel","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2010-02-267955","article-title":"IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status","volume":"116","author":"Schnittger","year":"2010","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation without FLT3 Internal Tandem Duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2010-12-322479","article-title":"The prognostic significance of IDH2 mutations in AML depends on the location of the mutation","volume":"118","author":"Green","year":"2011","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of Minimal Residual Disease in Standard-Risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: Data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: Results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin","year":"2012","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: A study from the German-Austrian acute myeloid leukemia study group","volume":"29","author":"Schlenk","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.3324\/haematol.2015.135467","article-title":"Droplet digital polymerase chain reaction for DNMT3A and IDH1\/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"101","author":"Brambati","year":"2016","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3324\/haematol.2017.183525","article-title":"Clinical relevance of IDH1\/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group","volume":"103","author":"Ferret","year":"2018","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3324\/haematol.2018.191148","article-title":"Persistent IDH1\/2 mutations in remission can predict relapse in patients with acute myeloid leukemia","volume":"104","author":"Ok","year":"2019","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1080\/10428194.2019.1585838","article-title":"Clinical value of molecular MRD monitoring by next-generation sequencing in patients with IDH2 mutated AML","volume":"60","author":"Shumilov","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"42345","DOI":"10.18632\/oncotarget.5645","article-title":"IDH1\/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: A study by the Acute Leukemia French Association","volume":"6","author":"Debarri","year":"2015","journal-title":"Oncotarget"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3109\/10428194.2012.727414","article-title":"Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene","volume":"54","author":"Jeziskova","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","first-page":"190","article-title":"Minimal Residual Disease assessment of IDH1\/2 mutations in Acute Myeloid Leukemia by LNA-RQ-PCR","volume":"94","author":"Abdelhamid","year":"2016","journal-title":"Tunis. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/leu.2011.215","article-title":"Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission","volume":"26","author":"Chou","year":"2012","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neo.2014.06.002","article-title":"Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia","volume":"16","author":"Kao","year":"2014","journal-title":"Neoplasia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/sj.leu.2401246","article-title":"Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes","volume":"12","author":"Verhagen","year":"1998","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","article-title":"Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations","volume":"20","author":"Gorello","year":"2006","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1093\/nar\/gnh036","article-title":"Strong positional preference in the interaction of LNA oligonucleotides with DNA polymerase and proofreading exonuclease activities: Implications for genotyping assays","volume":"32","author":"King","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clinbiochem.2018.08.012","article-title":"IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?","volume":"61","author":"Petrova","year":"2018","journal-title":"Clin. Biochem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13059-019-1659-6","article-title":"Analysis of error profiles in deep next-generation sequencing data","volume":"20","author":"Ma","year":"2019","journal-title":"Genome Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40291-014-0115-2","article-title":"Cytosine deamination is a major cause of baseline noise in next-generation sequencing","volume":"18","author":"Chen","year":"2014","journal-title":"Mol. Diagn. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41375-021-01368-1","article-title":"Indeterminate and oncogenic potential: CHIP vs. CHOP mutations in AML with NPM1 alteration","volume":"36","author":"Cappelli","year":"2022","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.leu.2404246","article-title":"Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples","volume":"20","author":"Cloos","year":"2006","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1525-1578(10)60458-8","article-title":"Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay","volume":"5","author":"Murphy","year":"2003","journal-title":"J. Mol. Diagn."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Carbonell, D., Chicano, M., Cardero, A.J., G\u00f3mez-Centuri\u00f3n, I., Bail\u00e9n, R., Oarbeascoa, G., Mart\u00ednez-Se\u00f1ar\u00eds, D., Franco, C., Mu\u00f1iz, P., and Anguita, J. (2022). FLT3-ITD Expression as a Potential Biomarker for the Assessment of Treatment Response in Patients with Acute Myeloid Leukemia. Cancers, 14.","DOI":"10.3390\/cancers14164006"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/bloodadvances.2018015925","article-title":"A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations","volume":"2","author":"Levis","year":"2018","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.lab.2005.03.005","article-title":"Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia","volume":"145","author":"Scholl","year":"2005","journal-title":"J. Lab. Clin. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","article-title":"Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML","volume":"114","author":"Schnittger","year":"2009","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2013-01-479188","article-title":"Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia","volume":"122","author":"Bullinger","year":"2013","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2141.2008.07488.x","article-title":"Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: Clonal evolution is a limiting factor","volume":"144","author":"Papadaki","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/gcc.22375","article-title":"Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia","volume":"55","author":"Pettersson","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/gcc.21955","article-title":"Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations","volume":"51","author":"Thol","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2014.104133","article-title":"Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse","volume":"99","author":"Hubmann","year":"2014","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Bill, M., Jentzsch, M., Bischof, L., Kohlschmidt, J., Grimm, J., Schmalbrock, L.K., Backhaus, D., Brauer, D., Goldmann, K., and Franke, G.N. (2022). Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation. Blood Adv., online ahead of print.","DOI":"10.1182\/bloodadvances.2021005789"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bjh.16857","article-title":"Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: Outcome after preemptive intervention based on measurable residual disease","volume":"191","author":"Bataller","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): An open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/24\/6205\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:42:16Z","timestamp":1760146936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/24\/6205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":50,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["cancers14246205"],"URL":"https:\/\/doi.org\/10.3390\/cancers14246205","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]}}}